Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of dialysis patients, subpar guidance for most of the year, uncertainty as to how much insurers were willing to continue reimbursing the company, and an embarrassing ransomware attack reported in April. It's just possible, however, that the sellers overshot their target. As of 12:16 p.m. ET Tuesday, DaVita stock ...

Group 1: Company Overview - DaVita Inc. (NYSE:DVA) specializes in kidney care services, primarily providing dialysis treatment for patients with chronic kidney failure and end-stage kidney disease in the United States [3] Group 2: Analyst Insights - David MacDonald from Truist lowered the price target on DaVita Inc. from $148 to $140 while maintaining a Hold rating on the stock [1] - The analyst remains broadly bullish on the healthcare industry, citing ongoing core strength in demand and improved visibility around the regulatory environment [2] - The firm appreciates the strong free cash flow and financial flexibility of the healthcare sector in general [2] Group 3: Investment Considerations - While DaVita is acknowledged as a potential investment, certain AI stocks are considered to offer greater upside potential and carry less downside risk [4]